Mechanism of action
Valaciclovir is rapidly converted to aciclovir by first-pass intestinal and hepatic metabolism via valaciclovir hydrolase. Aciclovir is then selectively activated within virus-infected cells through a three-step phosphorylation process.
Selective activation
The initial phosphorylation step is catalyzed by viral thymidine kinase (encoded by HSV and VZV), which has significantly greater affinity for aciclovir than host cellular kinases. This viral enzyme-dependent activation provides selectivity for infected cells. Subsequent phosphorylation to aciclovir diphosphate and triphosphate is carried out by host cellular kinases.
Viral DNA polymerase inhibition
Aciclovir triphosphate competitively inhibits viral DNA polymerase with much greater affinity than for human DNA polymerase (approximately 30-fold selectivity). It acts as both a competitive inhibitor and substrate for viral DNA polymerase. Once incorporated into the growing viral DNA chain, aciclovir triphosphate causes obligate chain termination because it lacks the 3'-hydroxyl group necessary for addition of subsequent nucleotides. The viral DNA polymerase becomes irreversibly bound to the terminated DNA chain, further inactivating the enzyme.
- Valaciclovir is converted to aciclovir, which requires viral thymidine kinase for initial phosphorylation, providing selectivity for infected cells
- Oral bioavailability of valaciclovir is 54% vs 15-20% for aciclovir, allowing less frequent dosing
- TTP/HUS is the most serious adverse effect, occurring primarily in immunocompromised patients on high doses (8 g/day)
- Dose adjustment is mandatory when creatinine clearance is below 50 mL/min to prevent neurotoxicity
- Aciclovir triphosphate acts as a DNA chain terminator lacking the 3'-OH group necessary for chain elongation
- Treatment of herpes zoster within 72 hours of rash onset reduces risk of postherpetic neuralgia
- Resistance mechanisms include mutations in viral thymidine kinase (most common) or viral DNA polymerase; treat with foscarnet
- Suppressive therapy reduces genital herpes transmission to partners by approximately 50%
Indications
Valaciclovir is indicated for multiple viral infections, primarily those caused by herpesviruses:
Herpes simplex virus infections
- Genital herpes: Treatment of initial and recurrent episodes, and chronic suppressive therapy to reduce frequency of recurrences and risk of transmission
- Orolabial herpes (cold sores): Treatment of recurrent episodes
- Herpes labialis: Early treatment reduces duration and severity
Varicella-zoster virus infections
- Herpes zoster (shingles): Treatment is most effective when initiated within 72 hours of rash onset; reduces acute pain, duration of viral shedding, and risk of postherpetic neuralgia
- Chickenpox (varicella): Used in immunocompetent adults and adolescents when treatment is initiated early
Cytomegalovirus prophylaxis
- Prevention of CMV disease in recipients of kidney, heart, or liver transplants (typically high-dose regimens)
- Off-label use for CMV prophylaxis in hematopoietic stem cell transplant recipients
Other uses
- Reduction of HIV transmission risk in HIV/HSV-2 co-infected patients (by suppressing HSV-2 reactivation and reducing genital ulcers)
- Prophylaxis of HSV reactivation in immunocompromised patients
Pharmacokinetics
Valaciclovir demonstrates significantly improved oral bioavailability compared to aciclovir, making it a more convenient therapeutic option.
Absorption: Rapidly absorbed from the gastrointestinal tract with bioavailability of approximately 54% (compared to 15-20% for aciclovir). Food does not significantly affect absorption. Peak plasma concentrations of aciclovir occur 1.5-2 hours after oral administration.
Distribution: Aciclovir is widely distributed throughout body tissues and fluids, including the brain, kidney, lungs, liver, aqueous humor, tears, and herpetic vesicle fluid. Cerebrospinal fluid concentrations reach approximately 50% of plasma levels. Plasma protein binding is low (9-33%). The volume of distribution is approximately 0.8 L/kg.
Metabolism: Valaciclovir undergoes rapid and nearly complete first-pass hydrolysis to aciclovir and L-valine by valaciclovir hydrolase. Less than 1% of administered valaciclovir is recovered unchanged in urine. Aciclovir is metabolized to a small extent (approximately 10%) to inactive metabolites via alcohol and aldehyde dehydrogenases.
Elimination: Primarily renal via glomerular filtration and active tubular secretion. The elimination half-life of aciclovir is approximately 2.5-3.3 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life is prolonged to approximately 14-20 hours, necessitating dose adjustment. Hemodialysis significantly removes aciclovir from plasma.
Adverse effects
Valaciclovir is generally well tolerated, with most adverse effects being mild to moderate in severity. The safety profile is similar to aciclovir due to the rapid conversion to the active drug.
Common adverse effects
- Gastrointestinal: Nausea, abdominal pain, diarrhea
- Neurological: Headache (most common, occurring in 13-35% of patients), dizziness
- General: Fatigue, malaise
Serious adverse effects
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): The most serious adverse effect, occurring rarely but predominantly in immunocompromised patients (advanced HIV/AIDS, transplant recipients). Characteristic findings include thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction, fever, and neurological changes. The mechanism is not fully understood but may involve direct endothelial toxicity. This typically occurs with high doses (8 g/day).
Acute kidney injury: Crystalline nephropathy can occur, particularly with rapid intravenous administration of aciclovir or in patients with pre-existing renal impairment or dehydration. Aciclovir crystals precipitate in renal tubules. Adequate hydration reduces risk.
Neurotoxicity: Rare but can manifest as encephalopathy, agitation, confusion, hallucinations, tremors, myoclonus, or seizures. More common in elderly patients, those with renal impairment, or with high doses. Symptoms typically resolve with dose reduction or discontinuation.
Other notable adverse effects
- Hepatic: Elevated liver enzymes (uncommon)
- Hematologic: Leukopenia, thrombocytopenia (rare)
- Dermatologic: Rash, photosensitivity
- Psychiatric: Depression, agitation (rare)
Contraindications and warnings
Contraindications
- Hypersensitivity to valaciclovir, aciclovir, or any component of the formulation
Warnings and precautions
Renal impairment: Dose adjustment is mandatory in patients with creatinine clearance below 50 mL/min to prevent drug accumulation and increased risk of neurotoxicity. Dosing should be guided by creatinine clearance, and adequate hydration should be maintained.
Elderly patients: Increased risk of adverse effects, particularly neurological manifestations, due to age-related decline in renal function. Careful monitoring and dose adjustment based on renal function are recommended.
Thrombotic microangiopathy risk: Patients with advanced HIV disease or transplant recipients receiving high doses for CMV prophylaxis require close monitoring for signs of TTP/HUS. Discontinue immediately if thrombotic microangiopathy is suspected.
Pregnancy: Classified as FDA pregnancy category B (no risk shown in animal studies, but inadequate human data). Large registry studies have not shown increased risk of birth defects with aciclovir exposure during pregnancy. May be used when benefits outweigh risks, particularly for primary HSV infection during pregnancy or severe recurrent genital herpes near term.
Lactation: Aciclovir is excreted in breast milk at concentrations 0.6-4.1 times maternal plasma levels. However, infant exposure is generally considered low, and breastfeeding is typically not contraindicated. The American Academy of Pediatrics considers aciclovir compatible with breastfeeding.
Transmission prevention: Valaciclovir reduces but does not eliminate the risk of transmission of genital herpes to partners. Patients should be counseled about safe sex practices and that asymptomatic viral shedding can still occur during suppressive therapy.
Drug interactions
Valaciclovir has relatively few clinically significant drug interactions due to minimal metabolism by cytochrome P450 enzymes and low plasma protein binding.
Nephrotoxic agents
Concurrent use with nephrotoxic drugs may increase the risk of renal dysfunction:
- NSAIDs: May reduce renal clearance of aciclovir
- Aminoglycosides, amphotericin B, cyclosporine, tacrolimus: Additive nephrotoxicity risk
- Intravenous contrast agents: Enhanced risk of acute kidney injury
Monitoring of renal function is advisable when these combinations are used.
Drugs affecting renal tubular secretion
Probenecid and cimetidine: Both inhibit active tubular secretion of aciclovir, potentially increasing plasma concentrations and prolonging elimination half-life. This interaction is generally not clinically significant but may require monitoring in patients with renal impairment.
Mycophenolate mofetil: Competition for renal tubular secretion may increase plasma concentrations of both aciclovir and the mycophenolic acid metabolite, particularly in patients with renal impairment. Clinical significance is unclear, but monitoring is prudent in transplant recipients.
Zidovudine
Some studies have reported increased drowsiness and lethargy with concurrent use, though the mechanism is uncertain. This interaction is of questionable clinical significance.
Tenofovir
No significant interaction, but both are renally eliminated, so caution and monitoring are appropriate in patients with renal impairment receiving both agents.
Other
No clinically significant interactions with antiretroviral agents (other than those mentioned), antibiotics, or most other commonly prescribed medications. The lack of hepatic metabolism eliminates most potential CYP450-mediated interactions.
Clinical pearls
- Prodrug advantage: Valaciclovir's 3-5 times higher bioavailability than aciclovir allows for less frequent dosing (typically 2-3 times daily vs. 5 times daily), significantly improving adherence, particularly in suppressive therapy.
- Timing matters for herpes zoster: Maximum benefit is achieved when treatment is initiated within 72 hours of rash onset. Early treatment significantly reduces the risk of postherpetic neuralgia, the most common complication of shingles in elderly patients.
- Suppressive therapy reduces transmission: Daily suppressive therapy for genital herpes reduces the risk of transmission to serodiscordant partners by approximately 50% and reduces frequency of recurrences by 70-80%.
- Resistance patterns: Aciclovir resistance is uncommon in immunocompetent patients (<1%) but occurs in 5-10% of immunocompromised patients, particularly those with AIDS or transplant recipients receiving prolonged therapy. Resistance typically results from mutations in viral thymidine kinase (most common) or viral DNA polymerase. Cross-resistance with other antivirals (famciclovir, ganciclovir) is common. Foscarnet is the treatment of choice for aciclovir-resistant HSV or VZV.
- Hydration is protective: Adequate hydration reduces the risk of crystalline nephropathy, particularly important in patients receiving high doses or with pre-existing renal impairment.
- Renal dosing is critical: Failure to adjust doses in renal impairment is a common prescribing error that significantly increases the risk of neurotoxicity. Always calculate creatinine clearance before prescribing.
- Pregnancy considerations: Valaciclovir is safe for treatment of primary genital herpes during pregnancy and for suppressive therapy starting at 36 weeks gestation to reduce the need for cesarean delivery in women with recurrent genital herpes.
- Bell's palsy: Though commonly prescribed, evidence for valaciclovir (with corticosteroids) in Bell's palsy is mixed, with modest benefit at best in severe cases.
Practice questions
1. A 67-year-old man with a history of kidney transplant 3 years ago presents with a painful vesicular rash in a dermatomal distribution on his left flank. He is started on high-dose valaciclovir for herpes zoster. Five days later, he develops fever, petechiae, and confusion. Laboratory studies show hemoglobin 8.2 g/dL, platelets 42,000/μL, creatinine 3.1 mg/dL (baseline 1.4 mg/dL), and schistocytes on peripheral blood smear. Which of the following is the most likely diagnosis?
2. A 28-year-old woman presents with her first episode of genital herpes at 34 weeks gestation. She is concerned about transmission to her baby during delivery. HSV-2 PCR from a genital lesion is positive. In addition to initiating treatment for the acute infection, which of the following is the most appropriate next step in management?
3. A 72-year-old woman with a history of chronic kidney disease (creatinine clearance 35 mL/min) is started on valaciclovir for herpes zoster. Three days later, she becomes increasingly confused and develops myoclonic jerks. Her family reports she has been taking the medication "as prescribed on the bottle" at the standard dose for normal renal function. Which of the following best explains her current presentation?
Frequently asked questions
How does valaciclovir work?
Valaciclovir is a prodrug that is rapidly converted to aciclovir in the body. Aciclovir is selectively activated by viral thymidine kinase in infected cells to form aciclovir triphosphate, which inhibits viral DNA polymerase and acts as a DNA chain terminator. This mechanism provides selectivity for virus-infected cells while sparing normal cells. The initial phosphorylation by viral thymidine kinase is the key step that allows the drug to accumulate preferentially in infected cells, achieving antiviral concentrations that inhibit herpes simplex virus and varicella-zoster virus replication.
What are the side effects of valaciclovir?
Common side effects include headache, nausea, abdominal pain, and dizziness. The most serious adverse effect is thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which occurs rarely but predominantly in immunocompromised patients receiving high doses. Acute kidney injury from crystalline nephropathy can occur, especially with dehydration or pre-existing renal impairment. Neurotoxicity manifesting as confusion, hallucinations, tremors, or seizures can develop, particularly in elderly patients or those with renal dysfunction. Most adverse effects are mild and self-limiting, with serious complications being uncommon when appropriate dosing and monitoring are employed.
Is valaciclovir safe during pregnancy?
Yes, valaciclovir is generally considered safe during pregnancy and is classified as FDA pregnancy category B. Large registry studies have not demonstrated increased risk of birth defects with aciclovir exposure during pregnancy. It is commonly used for treatment of primary genital herpes during pregnancy and for suppressive therapy starting at 36 weeks gestation in women with recurrent genital herpes to reduce viral shedding and the need for cesarean delivery. The benefits typically outweigh any theoretical risks, particularly for primary infections which pose greater risk to the fetus than the medication.
What is the difference between valaciclovir and aciclovir?
Valaciclovir is the L-valyl ester prodrug of aciclovir with significantly higher oral bioavailability (54% vs 15-20%). This means valaciclovir is much better absorbed from the gastrointestinal tract after oral administration. Once absorbed, valaciclovir is rapidly converted to aciclovir in the body, so the active antiviral agent is identical. The main advantage is that the improved bioavailability allows less frequent dosing—typically 2-3 times daily for valaciclovir versus 5 times daily for oral aciclovir—which significantly improves patient adherence. Both have similar efficacy and safety profiles since they produce the same active drug.
Does valaciclovir need dose adjustment in kidney disease?
Yes, dose adjustment is mandatory when creatinine clearance falls below 50 mL/min. Valaciclovir is eliminated primarily by the kidneys, and failure to adjust doses in renal impairment leads to drug accumulation and significantly increased risk of neurotoxicity. The extent of dose reduction depends on the degree of renal impairment, with more substantial reductions required as kidney function declines. In patients with end-stage renal disease on hemodialysis, dosing is typically given after dialysis sessions. Always calculate creatinine clearance before prescribing and adjust accordingly. Elderly patients often require dose adjustment due to age-related decline in renal function.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J05AB11
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.